Pharmacometric dose optimization of Buprenorphine in Neonatal Opioid Withdrawal Syndrome
نویسندگان
چکیده
منابع مشابه
Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome
Objective To examine the relationship between antepartum buprenorphine dose for medication-assisted treatment (MAT) of opioid use disorder (OUD) and incident neonatal opioid withdrawal syndrome (NOWS). Study Design We performed a prospective cohort study of pregnant women with a singleton gestation diagnosed with OUD and receiving buprenorphine for MAT at a tertiary care academic institution ...
متن کاملRevised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.
AIMS More than half of infants exposed to opioids in utero develop neonatal abstinence syndrome (NAS) of severity to require pharmacological therapy. Current treatments are associated with prolonged hospitalization. We sought to optimize the dose of sublingual buprenorphine in the treatment of NAS. DESIGN Randomized, Phase 1, open-label, active-control clinical trial comparing sublingual bupr...
متن کاملBuprenorphine Withdrawal Syndrome
The increasing use of buprenorphine among drug dependent subjects demands systematic enquiry into the clinical profile of buprenorphine withdrawal. Six male buprenorphine dependent (parenteral) subjects were observed for opiate withdrawal over a two week period. The onset of withdrawal occurred 48 hours after the last dose, peaked around the third day and lasted up to ten days. The withdrawals ...
متن کاملBuprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.
The dual antagonist effects of the mixed-action μ-opioid partial agonist/κ-opioid antagonist buprenorphine have not been previously compared in behavioral studies, and it is unknown whether they are comparably modified by chronic exposure. To address this question, the dose-related effects of levorphanol, trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide (U50,488...
متن کاملNeonatal paroxetine withdrawal syndrome.
Four term neonates presented with symptoms such as jitteriness and necrotising enterocolitis after paroxetine exposure in utero.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Translational Science
سال: 2021
ISSN: 1752-8054,1752-8062
DOI: 10.1111/cts.13074